<DOC>
	<DOCNO>NCT01022762</DOCNO>
	<brief_summary>This trial conduct Asia . The aim clinical trial investigate blood glucose lower effect safety profile repaglinide give alone compare gliclazide give alone Chinese subject type 2 diabetes never treat oral anti-diabetic drug ( OADs ) . This study also investigate augment effect repaglinide phase insulin secretion subgroup study .</brief_summary>
	<brief_title>Comparison Repaglinide Gliclazide Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Type 2 diabetes Oral antidiabetic drug ( OAD ) naïve ( unsystematic OAD treatment 6 month prior trial allow ) Insulin naïve ( le 1 week daily use insulin therapy trial start allow ) Lipidlowing agent naïve HbA1c : 6.58.5 % Fasting glucose : 6.113.0 mmol/L ( 110234 mg/dl ) Body Mass Index ( BMI ) : 2035 kg/m^2 Be able willing perform selfmonitored plasma glucose ( SMPG ) Be able willing eat 3 main meal per day Only applicable subject participate subgroup study : Be able willing perform complete IVGTT ( intravenous glucose tolerance test ) additional visit Known suspected allergy repaglinide , gliclazide , relate product ( example sulfonamide sulphonylureas ( SUs ) ) , excipients study drug Previous participation study Participation study another investigational drug within 1 month prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>